CD274 and hepatocellular carcinoma: In the more recent randomized, open-label, sponsor-blind, multicenter, global, phase 3 HIMALAYA trial, durvalumab (anti-PD-L1) monotherapy was found to be non-inferior to sorafenib (16.56 months vs. 13.77 months, respectively; p = 0.0035) and the combination of durvalumab plus tremelimumab (anti-CTLA-4) was shown to improve median OS over sorafenib (16.43 months vs. 13.77 months, respectively; p = 0.0035) in patients with unresectable HCC [12].